Clinical and Translational Science (Apr 2022)
Response to “iPTH is not a significant factor influencing the tacrolimus C/D ratio”
- Ryota Tanaka,
- Yosuke Suzuki,
- Hiroshi Watanabe,
- Takashi Fujioka,
- Kenshiro Hirata,
- Toshitaka Shin,
- Tadasuke Ando,
- Hiroyuki Ono,
- Ryosuke Tatsuta,
- Hiromitsu Mimata,
- Toru Maruyama,
- Hiroki Itoh
Affiliations
- Ryota Tanaka
- Department of Clinical Pharmacy Oita University Hospital Yufu‐shi, Oita Japan
- Yosuke Suzuki
- Department of Medication Use Analysis and Clinical Research Meiji Pharmaceutical University Kiyose, Tokyo Japan
- Hiroshi Watanabe
- Department of Biopharmaceutics Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto Japan
- Takashi Fujioka
- Laboratory of Medical Pharmaceutics Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
- Kenshiro Hirata
- Department of Clinical Pharmaceutics Faculty of Pharmaceutical Sciences Sojo University Kumamoto Japan
- Toshitaka Shin
- Department of Urology Faculty of Medicine Oita University Yufu‐shi, Oita Japan
- Tadasuke Ando
- Department of Urology Faculty of Medicine Oita University Yufu‐shi, Oita Japan
- Hiroyuki Ono
- Department of Clinical Pharmacy Oita University Hospital Yufu‐shi, Oita Japan
- Ryosuke Tatsuta
- Department of Clinical Pharmacy Oita University Hospital Yufu‐shi, Oita Japan
- Hiromitsu Mimata
- Department of Urology Faculty of Medicine Oita University Yufu‐shi, Oita Japan
- Toru Maruyama
- Department of Biopharmaceutics Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto Japan
- Hiroki Itoh
- Department of Clinical Pharmacy Oita University Hospital Yufu‐shi, Oita Japan
- DOI
- https://doi.org/10.1111/cts.13242
- Journal volume & issue
-
Vol. 15,
no. 4
pp. 807 – 808
Abstract
No abstracts available.
